Based on high-quality comparative studies, rituximab has demonstrated comparable or superior efficacy to cyclophosphamide in the treatment of GPA, particularly in relapsing cases or those associated with PR3-ANCA. This evidence concerns the gene PRTN3 and granulomatosis with polyangiitis.